Establishment Labs (NASDAQ:ESTA) Downgraded by Citigroup to Neutral

Establishment Labs (NASDAQ:ESTAGet Free Report) was downgraded by analysts at Citigroup from a “buy” rating to a “neutral” rating in a research note issued on Wednesday, Marketbeat.com reports. They currently have a $60.00 price objective on the stock. Citigroup’s price objective suggests a potential upside of 12.99% from the stock’s current price.

Several other equities research analysts have also recently weighed in on the stock. Mizuho increased their target price on shares of Establishment Labs from $50.00 to $65.00 and gave the company a “buy” rating in a research note on Monday, April 1st. JPMorgan Chase & Co. boosted their price target on shares of Establishment Labs from $46.00 to $53.00 and gave the company an “overweight” rating in a research report on Thursday, February 29th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Establishment Labs has a consensus rating of “Moderate Buy” and an average price target of $55.00.

Get Our Latest Stock Analysis on Establishment Labs

Establishment Labs Stock Down 0.4 %

Shares of Establishment Labs stock opened at $53.10 on Wednesday. The company has a current ratio of 4.24, a quick ratio of 2.73 and a debt-to-equity ratio of 3.38. Establishment Labs has a 1 year low of $16.96 and a 1 year high of $73.00. The stock has a 50-day moving average price of $51.91 and a 200 day moving average price of $39.08. The company has a market cap of $1.46 billion, a P/E ratio of -16.91 and a beta of 1.23.

Establishment Labs (NASDAQ:ESTAGet Free Report) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.58) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.07. Establishment Labs had a negative net margin of 53.12% and a negative return on equity of 206.05%. The company had revenue of $37.17 million for the quarter, compared to analyst estimates of $35.61 million. During the same quarter in the prior year, the business posted ($0.48) EPS. Establishment Labs’s quarterly revenue was down 20.1% on a year-over-year basis. As a group, analysts expect that Establishment Labs will post -1.73 EPS for the current fiscal year.

Institutional Trading of Establishment Labs

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brown Advisory Inc. raised its stake in shares of Establishment Labs by 63.9% during the fourth quarter. Brown Advisory Inc. now owns 2,428,792 shares of the company’s stock worth $62,881,000 after buying an additional 946,612 shares during the last quarter. Capital Research Global Investors bought a new stake in shares of Establishment Labs during the 1st quarter valued at $45,888,000. Fourth Sail Capital LP acquired a new position in shares of Establishment Labs in the 4th quarter valued at $14,473,000. William Blair Investment Management LLC acquired a new stake in shares of Establishment Labs during the first quarter worth $21,415,000. Finally, Cowen AND Company LLC increased its holdings in Establishment Labs by 18.1% in the third quarter. Cowen AND Company LLC now owns 1,141,172 shares of the company’s stock valued at $55,997,000 after purchasing an additional 175,000 shares during the last quarter. 72.91% of the stock is owned by institutional investors.

Establishment Labs Company Profile

(Get Free Report)

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.

Featured Articles

Analyst Recommendations for Establishment Labs (NASDAQ:ESTA)

Receive News & Ratings for Establishment Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Establishment Labs and related companies with MarketBeat.com's FREE daily email newsletter.